Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Rating of “Hold” by Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been assigned a consensus rating of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $8.10.

RXRX has been the subject of several recent research reports. Morgan Stanley boosted their price objective on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research report on Thursday, May 14th. Bank of America lowered their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st.

Recursion Pharmaceuticals Trading Down 3.0%

Shares of RXRX opened at $3.22 on Wednesday. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -2.68 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. Recursion Pharmaceuticals has a fifty-two week low of $2.77 and a fifty-two week high of $7.18. The firm has a 50 day moving average price of $3.31 and a 200-day moving average price of $3.80.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The business’s quarterly revenue was down 56.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.50) EPS. As a group, equities research analysts forecast that Recursion Pharmaceuticals will post -0.99 earnings per share for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $3.68, for a total value of $110,400.00. Following the completion of the sale, the director owned 6,169,863 shares in the company, valued at approximately $22,705,095.84. The trade was a 0.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the sale, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at $7,789,349.68. The trade was a 1.07% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 125,930 shares of company stock worth $435,942. 8.43% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. International Assets Investment Management LLC purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $31,000. Allworth Financial LP increased its position in Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after purchasing an additional 4,403 shares during the period. Sequoia Financial Advisors LLC purchased a new position in Recursion Pharmaceuticals during the 4th quarter valued at $41,000. IFP Advisors Inc increased its position in Recursion Pharmaceuticals by 81.5% during the 3rd quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock valued at $51,000 after purchasing an additional 4,650 shares during the period. Finally, Savant Capital LLC purchased a new position in Recursion Pharmaceuticals during the 3rd quarter valued at $54,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.